Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority
Zidan, H., Talaat, R., Ammar, A., Sakr, M. (2019). Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority. EKB Journal Management System, 77(1), 4742-4747. doi: 10.21608/ejhm.2019.46755
Hisham E Zidan; Randa M Talaat; Amal A A Ammar; Moustafa A Sakr. "Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority". EKB Journal Management System, 77, 1, 2019, 4742-4747. doi: 10.21608/ejhm.2019.46755
Zidan, H., Talaat, R., Ammar, A., Sakr, M. (2019). 'Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority', EKB Journal Management System, 77(1), pp. 4742-4747. doi: 10.21608/ejhm.2019.46755
Zidan, H., Talaat, R., Ammar, A., Sakr, M. Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority. EKB Journal Management System, 2019; 77(1): 4742-4747. doi: 10.21608/ejhm.2019.46755

Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority

The Egyptian Journal of Hospital Medicine
Article 11, Volume 77, Issue 1, October 2019, Page 4742-4747  XML PDF (527.78 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2019.46755
View on SCiNiTO View on SCiNiTO
Authors
Hisham E Zidan email 1; Randa M Talaat2; Amal A A Ammar1; Moustafa A Sakr2
1Department of Medical Researches, Nuclear Material Authority, Cairo
2Department of Molecular Diagnostics and Theraputics, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Menoufia, Egypt
Abstract
Background: A Single nucleotide polymorphism upstream of the interferon-λ3 gene (IFNL3; formerly referred to IL28B), strongly linked to unprompted and treatment-induced HCV infection clearance. Interleukin 28B genotype predictive value over the outcome interferon-α/ribavirin treatment was assessed carefully and contrasted with virological predictors Objective: The study aimed to evaluate IL-28B rs12979860 polymorphism in the reaction of HCV patients with directacting antiviral (DAA) regimens (sovosbuvir) and ribavirin therapy and the allele frequencies of this gene in Egyptian HCV patients working in the Egyptian Nuclear Materials Authority contrasted to healthy control. Subjects and Methods: The study was conducted on randomly chosen fifty Egyptian patients infected with genotype 4 HCV aged 30 or more and received antiviral therapy (sovosbuvir and ribavirin) before six months or more. Another Fifty age and gender matched apparantely healthy individuals were also selected as a control group. The study was carried out in accordance with the ethical principles and guidelines of the Declaration of Helsinki and a written informed consent was obtained from all subjects. Results:IL-28B genotype CC was found in 34.6% of patients, while CT and TT genotypes were identified in 42.3 and 23.1% of patients, respectively. Forty (40%) patients achieved an SVR, whereas ten (20%) did not. Of the 40 patients with an SVR, 12 had genotype CC, 25 had genotype CT, and 3 had genotype TT. CT genotype patients has achieved considerably higher SVR rates (62.5%) compared with CC (30%) and TT patients (7.5%). Conclusion: Polymorphism Il-28B is an autonomous predictor of SVR to Peg IFN / RBV in patients with genotype 4 in Egyptian HCV favorable.
Keywords
Interleukin 28B; hepatitis C; Sofosbuvir
Statistics
Article View: 334
PDF Download: 430